About

Seneca Therapeutics, Inc. (Seneca) is pursuing the development of an oncolytic immunotherapeutic called Seneca Valley Virus (SVV) and derivatives as cancer therapeutics, cancer vaccines, and vaccines for infectious diseases. SVV is an oncolytic virus that eliminates tumor cells in which it can replicate. SVV has shown promising activity in clinical studies conducted in patients having tumors of neuroendocrine origin, including small cell lung cancer. SVV has also been tested in numerous relevant animal models and can be utilized as a therapeutic for selected tumors. SVV can be further modified as a platform for delivery of gene products, immune system modifiers and tumor associated antigens to address a wide variety of cancers. Moreover, SVV can be modified for delivery of antigens for infectious disease vaccines.